As both p97 and ATX3 are druggable enzymes (Chou et al, 2014) and p97 inhibitors are in clinical trials for the treatment of several cancer types (Zhou et al, 2015), our findings pave the way for using p97 and ATX3 inhibitors as potential radiosensitisers clinically. This evidence concerns the gene ATXN3 and cancer.